Skp2 overexpression is a p27Kip1-independent predictor of poor prognosis in patients with biliary tract cancers

Cancer Science

Volumn 95, Issue 12, 2004, Pages 969-976

  Sanada, Takahiro ^a,b   Yokoi, Sana ^a,d   Arii, Shigeki ^b   Yasui, Kohichiroh ^a,d   Imoto, Issei ^a,d   Inazawa, Johji ^a,c,d  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Department of Surgery   (Japan)

^c Tokyo Medical and Dental University   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; CARRIER PROTEIN; CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; S PHASE KINASE ASSOCIATED PROTEIN; SIGNAL PEPTIDE;

ACCURACY; ADULT; AGED; AMPLICON; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CHROMOSOME 5P; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOLECULAR GENETICS; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL TIME; BILIARY TRACT TUMOR; COMPARATIVE STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; BILIARY TRACT NEOPLASMS; CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; S-PHASE KINASE-ASSOCIATED PROTEINS; SURVIVAL RATE;

EID: 11844306647     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2004.tb03185.x     Document Type: Article

References (37)

1. Japanese Society of Biliary Surgery. Classification of biliary tract carcinoma. 1st ed. Tokyo: Kanehara; 2001.
2. Lotze MT, Flickinger JC, Carr BI. Hepatobiliary neoplasms. In: DeVita VT, Hellman S, Rosenberg SA., editors. Cancer: Principles and oncology. 4th ed. Philadelphia, PA: J. B. Lippincott; 1993. p. 883-914.
3. Henson DE, Albores SJ, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer (Phila.) 1992; 70: 1498-501.
4. Henson DE, Albores SJ, Corle D. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer (Phila.) 1992; 70: 1493-7.
5. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138-41.
6. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science (Wash. DC) 1992; 258: 818-21.
7. Fukuda Y, Kurihara N, Imoto I, Yasui K, Yoshida M, Yanagihara K, Park JG, Nakamura Y, Inazawa J. CD44 is a potential target of amplification within the 11p13 amplicon detected in gastric cancer cell lines. Genes Chromosom Cancer 2000; 29: 315-24.
8. Yokoi S, Yasui K, Saito-Ohara F, Koshikawa K, Iizasa T, Fujisawa T, Terasaki T, Horii A, Takahashi T, Hirohashi S, Inazawa J. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol 2002; 161: 207-16.
9. Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara. A, Sugimoto T, Inazawa J. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 2003; 63: 1876-83.
10. Ariyama Y, Sakabe T, Shinomiya T, Mori T, Fukuda Y, Inazawa J. Identification of amplified DNA sequences on double minute chromosomes in a leukemic cell line KY821 by means of spectral karyotyping and comparative genomic hybridization. J Hum Genet 1998; 43: 187-90.
11. Yasui K, Arii S, Zhao C, Imoto I, Ueda M, Nagai H, Emi M, Inazawa J. TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology 2002, 35: 1476-84.
12. Imoto I, Tsuda H, Hirasawa A, Miura M, Sakamoto M, Hirohashi S, Inazawa J. Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res 2002; 62: 4860-6.
13. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek W. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 2001; 98: 5043-8.
14. Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I. Takata T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 2001; 61: 7044-7.
15. Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K, Nakayama K, Mori M. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 2002; 62: 3819-25.
16. Chiarle R, Fan Y, Piva R, Boggino H, Skolnik J, Novero D, Palestro G, De Wolf-Peeters C, Chilosi M, Pagano M, Inghirami G. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma. inversely correlates with p27 expression and defines cells in S phase. Am J Pathol 2002; 160: 1457-66.
17. Shiraishi K, Kusano N, Okita S, Oga A, Okita K, Sasaki K. Genetic aberrations detected by comparative genomic hybridization in biliary tract cancers. Oncology 1999; 57: 42-9.
18. Dowen SE, Neutze DM, Pett MR, Cottage A, Stern P, Coleman N, Stanley MA. Amplification of chromosome 5p correlates with increased expression of Skp2 in HPV-immortalized keratinocytes. Oncogene 2003; 22: 2531-40.
19. Kip1 expression and cyclin D1 overexpression, alone and in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma. Hepatology 1999; 30 1167-73.
20. Kip1 expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: association with cancer progression and prognosis. Hepatology 2000; 31: 1068-72.
21. KIP1 down-regulation. Mod Pathol 2002; 15: 1227-35.
22. Oliveira AM, Okuno SH, Nascimento AG, Lloyd RV. Skp2 protein expression in soft tissue sarcomas. J Clin Oncol 2003; 21: 722-7.
23. Dowen SE, Scott A, Mukherjee G, Stanley MA. Overexpression of Skp2 in carcinoma of the cervix does not correlate inversely with p27 expression. Int J Cancer 2003; 105: 326-30.
24. Bhattacharya S, Garriga J, Calbo J, Yong T, Haines DS, Grana X. SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells. Oncogene 2003; 22: 2443-51.
25. Cip1 in S phase. J Biol Chem 2003; 278: 25752-7.
26. von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya. C, Hydbring P, Weidung I, Nakayama K, Nakayama KI, Soderberg O, Kerppola TK, Larsson LG. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 2003; 11: 1189-200.
27. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates myc protein stability and activity. Mol Cell 2003; 11: 1177-88.
28. Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci USA 2003; 100: 10231-6.
29. KIP1 by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem 1999; 274: 13886-93.
30. Malek NP, Sundberg H, McGrew S, Nakayama K, Kyriakides TR, Roberts JM, Kyriakidis TR. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature 2001; 413: 323-7.
31. KiP1 at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway. J Biol Chem 2001; 276: 48937-43.
32. Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M, Meloche S. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 2001; 20: 6672-82.
33. Wirbelauer C, Sutterluty H, Blondel M, Gstaiger M, Peter M, Reymond F, Krek W. The F-box protein Skp2 is a ubiquitylation target of a Cu11-based core ubiquitin ligase complex: evidence for a role of Cu11 in the suppression of Skp2 expression in quiescent fibroblasts. EMBO J 2000; 19: 5362-75.
34. Imaki H, Nakayama K, Delehouzee S, Handa H, Kitagawa M, Kamura T, Nakayama KI. Cell cycle-dependent regulation of the Skp2 promoter by GA-binding protein. Cancer Res 2003; 63: 4607-13.
35. Shigemasa. K, Gu L, O'Brien TJ, Ohama K. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Clin Cancer Res 2003; 9: 1756-63.
36. Yokoi S, Yasui K, Iizasa T, Takahashi T, Fujisawa T, Inazawa J. Down-regulation of SKP2 induces apoptosis in lung-cancer cells. Cancer Sci 2003; 94: 344-9.
37. Mitchell BS. The proteasome - an emerging therapeutic target in cancer. N Engl J Med 2003; 348: 2597-8.